Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 99

1.

Antisense oligonucleotides: A primer.

Scoles DR, Minikel EV, Pulst SM.

Neurol Genet. 2019 Apr 1;5(2):e323. doi: 10.1212/NXG.0000000000000323. eCollection 2019 Apr. Review.

2.

[Antisense therapies for neurological diseases].

Pulst SM.

Nervenarzt. 2019 Jun 4. doi: 10.1007/s00115-019-0724-4. [Epub ahead of print] Review. German.

PMID:
31165208
3.

Antisense therapies for movement disorders.

Scoles DR, Pulst SM.

Mov Disord. 2019 Jul 8. doi: 10.1002/mds.27782. [Epub ahead of print] Review.

PMID:
31283857
4.

Oligonucleotide therapeutics in neurodegenerative diseases.

Scoles DR, Pulst SM.

RNA Biol. 2018;15(6):707-714. doi: 10.1080/15476286.2018.1454812. Epub 2018 Jun 1. Review.

5.

Antisense oligonucleotides in neurological disorders.

Wurster CD, Ludolph AC.

Ther Adv Neurol Disord. 2018 May 23;11:1756286418776932. doi: 10.1177/1756286418776932. eCollection 2018. Review.

6.

A Half-Century History of Applications of Antisense Oligonucleotides in Medicine, Agriculture and Forestry: We Should Continue the Journey.

Oberemok VV, Laikova KV, Repetskaya AI, Kenyo IM, Gorlov MV, Kasich IN, Krasnodubets AM, Gal'chinsky NV, Fomochkina II, Zaitsev AS, Bekirova VV, Seidosmanova EE, Dydik KI, Meshcheryakova AO, Nazarov SA, Smagliy NN, Chelengerova EL, Kulanova AA, Deri K, Subbotkin MV, Useinov RZ, Shumskykh MN, Kubyshkin AV.

Molecules. 2018 May 29;23(6). pii: E1302. doi: 10.3390/molecules23061302. Review.

7.

RNA-Targeted Therapies and Amyotrophic Lateral Sclerosis.

Mathis S, Le Masson G.

Biomedicines. 2018 Jan 15;6(1). pii: E9. doi: 10.3390/biomedicines6010009. Review.

8.

Precision Medicine through Antisense Oligonucleotide-Mediated Exon Skipping.

Li D, Mastaglia FL, Fletcher S, Wilton SD.

Trends Pharmacol Sci. 2018 Nov;39(11):982-994. doi: 10.1016/j.tips.2018.09.001. Epub 2018 Sep 30. Review.

PMID:
30282590
9.

Antisense oligonucleotides: the next frontier for treatment of neurological disorders.

Rinaldi C, Wood MJA.

Nat Rev Neurol. 2018 Jan;14(1):9-21. doi: 10.1038/nrneurol.2017.148. Epub 2017 Dec 1. Review.

PMID:
29192260
10.

Making sense of antisense oligonucleotides: A narrative review.

Goyal N, Narayanaswami P.

Muscle Nerve. 2018 Mar;57(3):356-370. doi: 10.1002/mus.26001. Epub 2017 Dec 27. Review.

PMID:
29105153
11.

Emerging antisense oligonucleotide and viral therapies for amyotrophic lateral sclerosis.

Ly CV, Miller TM.

Curr Opin Neurol. 2018 Oct;31(5):648-654. doi: 10.1097/WCO.0000000000000594. Review.

PMID:
30028737
12.

Antisense oligonucleotides: treating neurodegeneration at the level of RNA.

DeVos SL, Miller TM.

Neurotherapeutics. 2013 Jul;10(3):486-97. doi: 10.1007/s13311-013-0194-5. Review.

13.
14.

[Recent progress and prospect in oligonucleotide therapeutics].

Yoshioka K, Kuwahara H, Nishina K, Nagata T, Yokota T.

Nihon Rinsho. 2015 Jun;73(6):1057-65. Review. Japanese.

PMID:
26065142
15.

Recent Advances in Antisense Oligonucleotide Therapy in Genetic Neuromuscular Diseases.

Verma A.

Ann Indian Acad Neurol. 2018 Jan-Mar;21(1):3-8. doi: 10.4103/aian.AIAN_298_17. Review.

16.

Antisense Oligonucleotide-Based Therapy for Neuromuscular Disease.

Sardone V, Zhou H, Muntoni F, Ferlini A, Falzarano MS.

Molecules. 2017 Apr 5;22(4). pii: E563. doi: 10.3390/molecules22040563. Review.

17.

ASO Therapy: Hope for Genetic Neurological Diseases.

Muth CC.

JAMA. 2018 Feb 20;319(7):644-646. doi: 10.1001/jama.2017.18665. No abstract available.

PMID:
29383373
18.

Optimization of Morpholino Antisense Oligonucleotides Targeting the Intronic Repressor Element1 in Spinal Muscular Atrophy.

Osman EY, Washington CW 3rd, Kaifer KA, Mazzasette C, Patitucci TN, Florea KM, Simon ME, Ko CP, Ebert AD, Lorson CL.

Mol Ther. 2016 Sep;24(9):1592-601. doi: 10.1038/mt.2016.145. Epub 2016 Jul 9.

19.

Disarmed anthrax toxin delivers antisense oligonucleotides and siRNA with high efficiency and low toxicity.

Dyer PDR, Shepherd TR, Gollings AS, Shorter SA, Gorringe-Pattrick MAM, Tang CK, Cattoz BN, Baillie L, Griffiths PC, Richardson SCW.

J Control Release. 2015 Dec 28;220(Pt A):316-328. doi: 10.1016/j.jconrel.2015.10.054. Epub 2015 Nov 9.

20.

Estimated number of off-target candidate sites for antisense oligonucleotides in human mRNA sequences.

Yoshida T, Naito Y, Sasaki K, Uchida E, Sato Y, Naito M, Kawanishi T, Obika S, Inoue T.

Genes Cells. 2018 Jun;23(6):448-455. doi: 10.1111/gtc.12587. Epub 2018 Apr 18.

Supplemental Content

Support Center